ICMJE DISCLOSURE FORM

ate: <u>Jan. 8th, 2024</u>						
our Name: Erna Jia						
lanuscript Title: CCND2 is a prognostic biomarker and correlates with immune infiltration in lung adenocarcinoma						
Januscrint number (if known). TCP-22-1962-CI						

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Erna Jia None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Erna Jia None	
3	Royalties or licenses	Erna Jia None	
4	Consulting fees	Erna Jia None	

5	Payment or honoraria for	Erna Jia None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	Erna Jia None	
0	testimony	Ellia Jia Nolle	
	testimony		
7	Support for attending	Erna Jia None	
	meetings and/or travel		
8	Patents planned, issued or	Erna Jia None	
	pending		
9	Participation on a Data	Erna Jia None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	Erna Jia None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	Erna Jia None	
	•		
12	Receipt of equipment,	Erna Jia None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	Erna Jia None	
	financial interests		

Please summarize the above conflict of interest in the following box:

None			

Please place an "X" next to the following statement to indicate your agreement:

Erna Jia I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: <u>Jan. 8th, 2024</u>	
Your Name: Xianguan Shi	
Manuscript Title: CCND2 is a prognostic biomarker and correlates with immune infiltration in lung	
adenocarcinoma	
Manuscript number (if known): TCR-23-1863-CL	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Xianquan Shi None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Xianquan Shi None	
3	Royalties or licenses	Xianquan Shi None	
4	Consulting fees	Xianquan Shi None	

5	Payment or honoraria for	Xianquan Shi None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	NI 01111	
6	Payment for expert	Xianquan Shi None	
	testimony		
7	Support for attending	Xianguan Shi None	
,	meetings and/or travel	Alanquan 3m None	
8	Patents planned, issued or	Xianquan Shi None	
	pending		
9	Participation on a Data	Xianquan Shi None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	Xianquan Shi None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	Xianquan Shi None	
12	Receipt of equipment,	Xianquan Shi None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	Xianquan Shi None	
	financial interests		

Please summarize the above conflict of interest in the following box:

None			

Please place an "X" next to the following statement to indicate your agreement:

Xianquan Shi I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

ICMJE DISCLOSURE FORM

Date: Jan. 8th, 2024	
Your Name: <u>Jinru Xue</u>	
Manuscript Title: CCND2 is a	prognostic biomarker and correlates with immune infiltration in lung
<u>adenocarcinoma</u>	
Manuscript number (if known):	TCR-23-1863-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Jinru Xue None	
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	Jinru Xue None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	Jinru Xue None	
	o lii c		
4	Consulting fees	Jinru Xue None	

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	
speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Jinru Xue None Jinru Xue None Jinru Xue None Jinru Xue None	
testimony Support for attending meetings and/or travel	
8 Patents planned, issued or pending 9 Participation on a Data Jinru Xue None Jinru Xue None Jinru Xue None	
pending 9 Participation on a Data Jinru Xue None	
pending 9 Participation on a Data Jinru Xue None	
pending 9 Participation on a Data Jinru Xue None	
9 Participation on a Data Jinru Xue None	
Safety Monitoring Board or	
Advisory Board	
10 Leadership or fiduciary role in other board, society, Jinru Xue None	
committee or advocacy group, paid or unpaid	
11 Stock or stock options Jinru Xue None	
12 Receipt of equipment, Jinru Xue None	
materials, drugs, medical	
writing, gifts or other services	
13 Other financial or non- Jinru Xue None	
financial interests	

Please summarize the above conflict of interest in the following box:

None			

Please place an "X" next to the following statement to indicate your agreement:

Jinru Xue I certify that I have answered every question and have not altered the wording of any of the questions on this form.